Acquisition of Pionyr - Additional Information (Details) - IKENA ONCOLOGY INC - Pionyr Immunotherapeutics, Inc $ in Millions |
Aug. 04, 2023
USD ($)
shares
|
---|---|
Business Acquisition [Line Items] | |
Business acquisition, contingent value right received for each share | 1 |
Percentage of net proceeds from potential monetization of legacy programs receivable | 50.00% |
Business acquisition, transaction cost | $ | $ 1.3 |
Common Stock | |
Business Acquisition [Line Items] | |
Business acquisition, shares issued | 150,054 |
Non-voting Common Stock | |
Business Acquisition [Line Items] | |
Business acquisition, shares issued | 12,760 |
Series A Preferred Stock | |
Business Acquisition [Line Items] | |
Business acquisition, shares issued | 4,153,439 |